{"title":"玻璃体内抗血管内皮生长因子药物的免疫原性和眼内炎症的可能性","authors":"Hyeong Min Kim MD, MSc , Se Joon Woo MD, PhD","doi":"10.1016/j.curtheres.2024.100742","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Concerns of intraocular inflammation associated with intravitreal administration of anti-VEGF drugs have been risen and the exact mechanism is not yet elucidated.</p></div><div><h3>Objective</h3><p>To explore the relationship between immunogenicity and intraocular inflammation in intravitreal anti-VEGF drugs.</p></div><div><h3>Methods</h3><p>This review examines the immunogenicity of individual intravitreal anti-VEGF drugs and their potential link to intraocular inflammation.</p></div><div><h3>Results</h3><p>We suggest that the main cause of intraocular inflammation is the presence of pre-existing and treatment-induced antidrug antibodies, along with considerations related to the molecular structure, which includes the drug's format and size.</p></div><div><h3>Conclusions</h3><p>Researchers and clinicians involved in the advancement of new anti-VEGF drugs should take into consideration the factors related to intraocular inflammation that have been discussed.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100742"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000122/pdfft?md5=726046823de302fc9e832324390aa5ae&pid=1-s2.0-S0011393X24000122-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs\",\"authors\":\"Hyeong Min Kim MD, MSc , Se Joon Woo MD, PhD\",\"doi\":\"10.1016/j.curtheres.2024.100742\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Concerns of intraocular inflammation associated with intravitreal administration of anti-VEGF drugs have been risen and the exact mechanism is not yet elucidated.</p></div><div><h3>Objective</h3><p>To explore the relationship between immunogenicity and intraocular inflammation in intravitreal anti-VEGF drugs.</p></div><div><h3>Methods</h3><p>This review examines the immunogenicity of individual intravitreal anti-VEGF drugs and their potential link to intraocular inflammation.</p></div><div><h3>Results</h3><p>We suggest that the main cause of intraocular inflammation is the presence of pre-existing and treatment-induced antidrug antibodies, along with considerations related to the molecular structure, which includes the drug's format and size.</p></div><div><h3>Conclusions</h3><p>Researchers and clinicians involved in the advancement of new anti-VEGF drugs should take into consideration the factors related to intraocular inflammation that have been discussed.</p></div>\",\"PeriodicalId\":10920,\"journal\":{\"name\":\"Current Therapeutic Research-clinical and Experimental\",\"volume\":\"100 \",\"pages\":\"Article 100742\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0011393X24000122/pdfft?md5=726046823de302fc9e832324390aa5ae&pid=1-s2.0-S0011393X24000122-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Therapeutic Research-clinical and Experimental\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0011393X24000122\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X24000122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs
Background
Concerns of intraocular inflammation associated with intravitreal administration of anti-VEGF drugs have been risen and the exact mechanism is not yet elucidated.
Objective
To explore the relationship between immunogenicity and intraocular inflammation in intravitreal anti-VEGF drugs.
Methods
This review examines the immunogenicity of individual intravitreal anti-VEGF drugs and their potential link to intraocular inflammation.
Results
We suggest that the main cause of intraocular inflammation is the presence of pre-existing and treatment-induced antidrug antibodies, along with considerations related to the molecular structure, which includes the drug's format and size.
Conclusions
Researchers and clinicians involved in the advancement of new anti-VEGF drugs should take into consideration the factors related to intraocular inflammation that have been discussed.
期刊介绍：
We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics.
CTR encourages and supports the submission of manuscripts describing:
• Interventions designed to understand or improve human health, disease treatment or disease prevention;
• Studies that focus on problems that are uncommon in resource-rich countries;
• Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing);
• Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English;
• Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
